G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 -- Reaffirmed 2024 Net COSELA..
Therapeutic Goods Administration
News and Video Search Results
News coverage
-
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
GlobeNewswire
-
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
GlobeNewswire
-
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
-
Q1 2024 Revenue and Business Update
GlobeNewswire
0 shares
4 views
You might like
Therapeutic Goods Administration media coverage
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
GlobeNewswire
· FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging
· Collaboration agreement..
-
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
GlobeNewswire
-
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
Accesswire
-
Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
GlobeNewswire
-
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
Advertisement
More coverage
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
GlobeNewswire
SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877;..
-
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
GlobeNewswire
-
Inhalation Capsules Market to Reach $1.5 Billion Globally by 2032 at 6.4% CAGR: Allied Market Research
GlobeNewswire
-
Robert Reich: My Mentor And Friend, Ken Galbraith – OpEd
Eurasia Review
-
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
GlobeNewswire